Sahyadri Hospitals, a prominent hospital chain in Maharashtra, has joined forces with ImmunoACT to bring CAR-T cell therapy to Pune.

The groundbreaking NexCAR19 therapy offers a revolutionary approach for the treatment of relapsed B-cell lymphoma and B-acute lymphoblastic leukemia patients.

CAR-T cell therapy involves genetically modifying a patient’s T-cells to specifically target cancer cells. NexCAR19, hailed as the first fully developed and manufactured Indian CAR-T therapy, is poised to be provided at a fraction of the cost compared to similar therapies in the United States. Initially available at Sahyadri’s Deccan Gymkhana center in Pune, NexCAR19 will cater to patients across western India.

Abrarali Dalal, Director & CEO of Sahyadri Hospitals, emphasized the hospital's commitment to providing optimal care for cancer patients, stating, "CAR-T cell therapy showcases our dedication to giving cancer patients the best care. This new method is part of our ongoing effort to improve cancer treatment with the latest options."

Dr. Shashikant Apte, Head of the Department of Haematology & Bone Marrow Transplant Unit at Sahyadri Hospitals, highlighted the potential of NexCAR19 in assisting B-cell cancer patients, expressing the hospital's eagerness to explore more cell therapies for other blood cancers.

Shirish Arya, Co-Founder and Director of Business Development & Corporate Strategy at ImmunoACT, shared, "We support Sahyadri Hospitals to offer NexCAR19 affordably. ImmunoACT aims to make CAR-T therapy more accessible."

This collaboration marks a significant step in advancing cancer treatment options in India, with the introduction of a cost-effective and locally developed CAR-T cell therapy that holds promise for patients facing challenging hematological conditions.